T Cell Memory Fuels the Innate Response in Chronic CF Lung Disease

Cystic Fibrosis Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04397861
• Other study ID #: SAAVED16GO
• Status: Completed
• Start date: May 6, 2015
• Est. completion date: November 1, 2021

Study information

• Verified date: September 2022
• Source: National Jewish Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study seeks to define the role of CD4+ and CD8+ T cell memory responses in the immunologic failure of patients with cystic fibrosis (CF) to clear infections. In a normal host, the immune system clears pathogens upon re-infection more swiftly and efficiently than during an initial infection, in great part due to the recall and effector functions of memory T cells. In CF, far less is understood regarding the response of T cell memory when hosts reencounter antigens, otherwise known as pulmonary exacerbations. Pulmonary exacerbations are pivotal events that lead to a decline in health status among CF patients, with many never recovering to baseline health. CF patients will be recruited from patients followed by the Adult CF Program at National Jewish Health. Following enrollment at the time of antibiotic initiation, blood will be collected at two different time points. The first samples will be collected within 24 hours of starting IV antibiotic therapy. The second blood specimen will be collected at the end of hospitalization, after a minimum of 5 days. At the time of each blood draw, complete blood counts, a sputum sample, and simple spirometry will be measured as part of the standard care of a CF exacerbation. Isolated PBMCs will be stained with antibodies to designate cell surface phenotype. They will then be sorted to identify the T cell population. These cells will be tested on their ability to clear pathogens. The relationship between cellular immune responses and clinical indicators of pulmonary status will be examined by fitting linear mixed models.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 112
• Est. completion date: November 1, 2021
• Est. primary completion date: May 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documented diagnosis of CF.

• Age 18 years old or greater.

• Hospitalization with planned IV antibiotic treatment for a pulmonary exacerbation of CF.

• Ability to perform reproducible Pulmonary Function Tests and produce sputum.

• Willingness to comply with study procedure and willingness to provide written consent.

Exclusion Criteria:

• Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or the quality of the data.

• Use of systemic steroids at the start of IV treatment for a pulmonary exacerbation

Related Conditions & MeSH terms

• Cystic Fibrosis

Locations

Country	Name	City	State
United States	National Jewish Health	Denver	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
National Jewish Health	Cystic Fibrosis Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate CD4+ and CD8+ T cell function during CF pulmonary exacerbation	Prospectively evaluate CD4+ and CD8+ T cell function as measured from the peripheral blood in patients with cystic fibrosis (CF) and its correlation with improvements in pulmonary inflammation and clinical status during treatment of CF pulmonary exacerbations.	average 10 days
Primary	Evaluate CD4+ and CD8+ T cell function during CF pulmonary exacerbation	Prospectively evaluate CD4+ and CD8+ T cell function as measured from the peripheral blood in patients with cystic fibrosis (CF) and its correlation with improvements in pulmonary inflammation and clinical status during treatment of CF pulmonary exacerbations.	a period of 60 months
Primary	Test the capacity of enhanced CFTR activity to bolster host inflammatory cell function	Compare CF effector memory responses between those clinically prescribed a CFTR modulator and those not currently on treatment as measured by flow cytometry. The ability of CF effector T cells to control infection over time will change over the subject's lifetime and use of CFTR modulators.	average 10 days
Primary	Test the capacity of enhanced CFTR activity to bolster host inflammatory cell function	Compare CF effector memory responses between those clinically prescribed a CFTR modulator and those not currently on treatment as measured by flow cytometry. The ability of CF effector T cells to control infection over time will change over the subject's lifetime and use of CFTR modulators.	a period of 60 months
Primary	Test the capacity of T cell subsets to control infection over time	Compare CF effector memory responses between those who are infected frequently (2 or more times/year) and those infected infrequently (0-1 times/year) as measured by flow cytometry. The ability of CF effector T cells to control infection over time will change over the subject's lifetime and number of exacerbations.	average 10 days
Primary	Test the capacity of T cell subsets to control infection over time	Compare CF effector memory responses between those who are infected frequently (2 or more times/year) and those infected infrequently (0-1 times/year) as measured by flow cytometry. The ability of CF effector T cells to control infection over time will change over the subject's lifetime and number of exacerbations.	a period of 60 months